EcoDrugPlus

Ribosomal Protein S29

Ensembl ID : ENSOJAG00000023319
Gene Symbol: RPS29
1 Cross references
268 Possible Orthologues:

Ribosomal Protein S5

Ensembl ID : ENSOJAG00000002784
Gene Symbol: RPS5
1 Cross references
264 Possible Orthologues:

Ribosomal Protein S9

Ensembl ID : ENSOJAG00000008456
Gene Symbol: RPS9
1 Cross references
235 Possible Orthologues:

Serpin Peptidase Inhibitor, Clade C (Antithrombin), Member 1

Ensembl ID : ENSOJAG00000001862
Gene Symbol: SERPINC1
1 Cross references
199 Possible Orthologues:

Si:dkey-211g8.6

Ensembl ID : ENSOJAG00000006606
Gene Symbol: SI:DKEY-211G8.6
1 Cross references
320 Possible Orthologues:

Si:dkey-91m11.5

Ensembl ID : ENSOJAG00000014051
Gene Symbol: SI:DKEY-91M11.5
1 Cross references
196 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSOJAG00000018866
Gene Symbol: SMO
1 Cross references
204 Possible Orthologues:

Sodium Channel, Voltage Gated, Type V-Like, Alpha B

Ensembl ID : ENSOJAG00000013849
Gene Symbol: SCN5LAB
1 Cross references
256 Possible Orthologues:

Sodium Channel, Voltage Gated, Type Xii, Alpha A

Ensembl ID : ENSOJAG00000002053
Gene Symbol: SCN12AA
1 Cross references
248 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSOJAG00000017595
Gene Symbol: SCN8A
1 Cross references
216 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSOJAG00000021181
Gene Symbol: SCN8A
1 Cross references
215 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSOJAG00000009355
Gene Symbol: SLC10A2
1 Cross references
214 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).